Q3 2025 revenues were $11.5 million, up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history. Q3 2025 gross margin was 77.9%, versus 75.5% in Q3 2024. GAAP Operating Income was $1.5 million for Q3 2025 versus $2.0 million in Q3 2024. Q3 2025 included stock-based compensation costs of $1.4 million versus $0 in Q3 2024. Company provides guidance for revenues of $13-$14 million for... Read More

EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, November 7, 2025, at 8:30 AM (ET) to present its Q3 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information... Read More

CMS adopts Final Rule for 2026 Physician Fee Schedule in line with proposed rule for CPT code 97610 2026 rates for physician offices, home visits, long-term care, and hospitals are in line with the proposed rule and remain materially unchanged from 2025 EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved... Read More

Sanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the highest quarterly revenues in Company history. Q3 2025 revenue increased between 22% and 24% vs Q3 2024 and between 12% and 14% sequentially vs the prior quarter First nine months of 2025 revenue increased 39-40% vs first nine months of 2024. EDEN PRAIRIE, Minn., Oct. 06, 2025 (GLOBE... Read More

Credit facility from J.P. Morgan consists of a four-year term loan of $23 million and a two-year $5 million revolving credit facility backed by accounts receivable Both the term loan and revolver have an interest rate of SOFR +350bp The Company drew approximately $1 million from the revolver at commencement, resulting in total outstanding debt under the new facility of approximately $24 million. Company announces the... Read More

Q2 2025 revenues were $10.2 million, up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 gross margin was 78.3%, versus 73.2% in Q2 2024. GAAP Operating Income was $1.9 million for Q2 2025 versus $2.0 million in Q2 2024. Q2 2025 included equity compensation costs of $1.1 million versus $0 in Q2 2024. Company provides guidance for revenues of $12-$12.7 million for... Read More

EDEN PRAIRIE, Minn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 8, 2025, at 8:30 AM (ET) to present its Q2 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information... Read More

EDEN PRAIRIE, Minn., July 22, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ: SNWV), a leading provider of next-generation, FDA-approved wound care products , today announced, that Morgan Frank, Chief Executive Officer, will present at the 45th Annual Canaccord Genuity Growth Conference, being held August 12–13, 2025, at the InterContinental Hotel in Boston, Massachusetts. Sanuwave’s group presentation is scheduled... Read More

Sanuwave is pleased to announce preliminary revenues of $10.1 million to $10.2 million for the second quarter ended June 30, 2025. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 revenue increased between 41% and 42% compared to Q2 2024. First half of 2025 revenue increased 50-51% vs first half of 2024. EDEN PRAIRIE, Minn., July 14, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company"... Read More

Libby brings strong team building, growth, and sales operations and systems skills to Sanuwave after a career of growing startups into mid- and large-sized companies. EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Dustin Libby as its EVP of... Read More

EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ: SNWV), a leading provider of next-generation, non-invasive wound care solutions, today announced, as part of the 2025 Russell indexes reconstitution, the Company’s inclusion in the Russell 2000® Index. This will be effective after the U.S. market opens on June 30. In addition to the Russell 2000® Index, the Company is also expected to be... Read More

Bazar brings decades of experience in engineering, computer science and cyber security, AI, and business intelligence over a career of building successful companies EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (Nasdaq:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of Greg Bazar to its Board of... Read More

Q1 2025 revenues were $9.3 million, up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 gross margin was 79.0%, versus 72.6% in Q1 2024. GAAP Operating Income was $1.0 million for Q1 2025, an increase of $2.0 million from Q1 2024. Company provides guidance for revenue growth of 40-50% for Q2 2025 as compared to Q2 2024 EDEN PRAIRIE, Minn., May 09, 2025 (GLOBE... Read More

EDEN PRAIRIE, Minn., May 05, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, May 9, 2025, at 8:30 AM (ET) to present its Q1 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll... Read More

SANUWAVE is pleased to announce preliminary revenues of $9.1 million to $9.3 million for the first quarter ended March 31, 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 revenue increased between 57% and 61% compared to Q1 2024. UltraMIST revenues for Q1 2025 increased by more than 65% versus Q1 2024 and accounted for approximately 99% of the Company’s total revenues. EDEN PRAIRIE, Minn.,... Read More

Q4 2024 revenues were $10.3 million, up 47% from Q4 2023. This was an all-time quarterly record for the Company. Full year 2024 revenues were $32.6 million, up 60% from full year 2023 revenues. This was an all-time annual record for the Company. Q4 2024 gross margin was 77.9%, versus 69.1% in Q4 2023 and 75.5% in Q3 2024. Full year 2024 gross margin was 75.2% versus 70.4% in 2023. GAAP Operating Income was $2.5 million for... Read More

EDEN PRAIRIE, Minn. / Mar 17, 2025 / Business Wire / SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, March 21, 2025, at 8:30 AM (ET) to present its Q4 and Full Year 2024 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in... Read More

EDEN PRAIRIE, Minn., March 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or "Sanuwave”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, announced today that its common stock has been approved for listing on the Nasdaq Global Market (“Nasdaq”). Trading on Nasdaq is expected to commence at the market open on March 7, 2025, with shares continuing to trade under the... Read More

EDEN PRAIRIE, Minn., Feb. 19, 2025 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that Morgan Frank, Chief Executive Officer, will participate in the 37 th Annual Roth Conference to be held on March 16-18 at the Laguna Cliffs Marriott Resort & Spa in Dana Point, California. Management will be available for one-on-one meetings... Read More

Q3 2024 revenues were $9.4 million, up 89% from Q3 2023. This was an all-time quarterly record for the Company. Q3 2024 gross margin was 75.5%, vs 71.5% in Q3 2023 GAAP Operating Income was $2.0 million Company provides guidance for revenue growth of 40-50% for Q4 2024 versus Q4 2023 EDEN PRAIRIE, Minn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of... Read More

EDEN PRAIRIE, Minn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, November 8, 2024, at 8:30 AM (ET) to present its Q3 2024 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information... Read More

1-for-375 reverse stock split effective at market open today Exchanged $43.2 million in principal amount of convertible notes and warrants previously exercisable for approximately 1.7 billion pre-split shares for approximately 4.0 million post-split shares Closed $10.3 million equity only PIPE offering at $8.25 per share of common stock led by certain institutional investors, including AWM Investment Company, Inc., the... Read More

Common Stock Will Begin Trading on a Split-adjusted Basis on October 18, 2024 EDEN PRAIRIE, Minn., Oct. 16, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that, effective at 12:01 a.m. Mountain Time on October 18, 2024, the Company will implement a 1-for-375 reverse stock split of its... Read More

Q2 2024 revenues were $7.2 million, up 53% from Q2 2023. This was an all-time quarterly record for the Company. Q2 2024 Gross Margin was 73%, vs 74% in Q2 2023 GAAP Operating Income was $2.0 Million Company Provides Guidance for Revenue Growth of 65-75% for Q3 2024 Versus Q3 2023 EDEN PRAIRIE, MN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of... Read More

SANUWAVE is pleased to announce preliminary revenues of $5.7 million to $5.9 million for the first quarter ended March 31, 2024. This represents the highest Q1 revenues in company history. Q1 2024 revenue increased between 51% and 56% compared to Q1 2023. UltraMist revenues for Q1 2024 increased by more than 55% versus Q1 2023 and accounted for approximately 95% of the Company’s total revenues. UltraMist applicator sales... Read More

Sorensen brings strong finance, forecasting, analysis, and capital markets experience as well as abilities in software, process automation, and human resources to SANUWAVE EDEN PRAIRIE, MN, April 01, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Peter... Read More

Q4 2023 revenues were a record $7.0 million, up 27% from Q4 2022 FY 2023 revenues were a record $20.4 million, up 22% from FY2022 Operating income was $1 million for Q4 2023 compared to an operating loss of $1.5 million for Q4 2022 Company provides guidance for revenue growth of 45-55% for Q1 2024 vs Q1 2023 and initiates annual guidance for FY2024 of 50% revenue growth vs. FY2023 EDEN PRAIRIE, MN, March 22, 2024 (GLOBE... Read More

EDEN PRAIRIE, MN, March 20, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "Sanuwave”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, March 22, 2024, at 8:30 AM (ET) to present the Q4 and FY2023 financial results Telephone access to the call will be available by dialing the following numbers: Participant... Read More

At a special meeting of stockholders on February 21, 2024, SANUWAVE stockholders approved the business combination with SEP Acquisition Corp. by a vote of 798,379,869 “for” and 5,221,765 “against” with 71,525 abstaining 70.5% of all shares eligible to vote in this special election either voted or abstained Of those who voted, 99.3% voted “for” and 0.7% voted “against” with 0% (rounded to the nearest 1/10 th of one percent)... Read More

EDEN PRAIRIE, MN, Jan. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced the Company is holding a special meeting of stockholders on February 21, 2024 at 10:00 a.m. CT (11:00 a.m. ET) to vote on the previously announced merger with SEP Acquisition Corp (“SEPA”). SANUWAVE... Read More

SANUWAVE is pleased to announce preliminary revenues of $6.6 million to $6.8 million for the fourth quarter ended December 31, 2023. This represents a new quarterly revenue record for the Company. Q4 2023 revenue increased 20% to 24% over Q4 2022 and in excess of 30% versus the third quarter of 2023. Preliminary FY 2023 revenue range was $20.0 million to $20.2 million, an increase of 19% to 20% year over year. This... Read More

EDEN PRAIRIE, MN,, Nov. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced its 3rd quarter 2023 results. For the three months ended September 30, 2023: Revenue for the three months ended September 30, 2023 totaled $5.0 million, an increase of 19%, as compared to $4.2 million... Read More

EDEN PRAIRIE, MN, Nov. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation wound care products, will host a live conference call on Friday, November 10, 2023, at 8:00AM (ET) to present the Q3 2023 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Listening: 1-877-407-0784 or 1-201-689-8560... Read More

SANUWAVE is Pleased to Announce Preliminary Revenues of $4.7 Million to $4.9 Million for the Third Quarter Ended September 30, 2023 Results Indicate 13-18% Growth Rate Over Q3 2022 UltraMist Revenues (systems and consumables) Increased in Excess of 25% Year On Year and by Greater Than 10% vs Q2 2023 EDEN PRAIRIE, MN, Oct. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”)... Read More

SANUWAVE Health Inc. (OTCQB: SNWV) has entered into a definitive merger agreement with SEP Acquisition Corp. (Nasdaq: SEPA). Upon closing, the combined company is expected to trade on the Nasdaq Capital Market under the symbol “SNWV”. The combined company expects to receive approximately $13.0 million of gross proceeds at closing, including $12.0 million from non-redeeming holders of SEPA’s Class A common stock and other... Read More

EDEN PRAIRIE, MN, Aug. 11, 2023 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced its 2nd quarter 2023 results. For the three months ended June 30, 2023: Revenue for the three months ended June 30, 2023 totaled $4.7 million, an increase of 20%, as compared to $3.9 million for the same period of 2022.... Read More

EDEN PRAIRIE, MN, Aug. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 11, 2023, at 8:30AM (EDT) to present its Q2 2023 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Listening: 1-877-407-0784 or... Read More

Pacific Medical to bring its sales force of over 215 dedicated representatives covering seven western states to the SANUWAVE UltraMist line of directed energy wound care products. Long-term agreement to develop and expand the market for SANUWAVE “Energy First” treatments. EDEN PRAIRIE, MN, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB:SNWV), a leading provider... Read More

Walko brings 17 years of Manufacturing, Production, Operations, and Logistics Experience, most recently as President of Biomerics, where he led a 170-person contract manufacturing organization EDEN PRAIRIE, MN, July 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce... Read More

SANUWAVE is pleased to announce preliminary revenues of $4.5 million to $4.7 million for Q2 ended June 30, 2023 Results indicate 16-21% growth rate over Q2 2022, consistent with guidance provided in the Q1 2023 earnings release EDEN PRAIRIE, MN, July 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care... Read More

Frank Brings 29 Years of Experience in Life Sciences, Technology, and Capital Markets Kevin Richardson to Remain at SANUWAVE as Chief Strategic Officer and as a Member of the Board of Directors EDEN PRAIRIE, MN, May 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB:SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that its... Read More

EDEN PRAIRIE, MN, May 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced 1st quarter 2023 results. For the three-months ended March 31, 2023: Revenues increased 18% to $3.8 million for Q1 2023 versus $3.2 million for the same period last year. This growth falls within the guidance range of 14-20%,... Read More

EDEN PRAIRIE, MN, May 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation wound care products, will host a live conference call on Friday, May 12, 2023, at 9:00AM (EDT) to discuss a financial update and recent strategic initiatives. Telephone access to the call will be available by dialing the following numbers: Participant Listening: 1-877-407-0784 or... Read More

EDEN PRAIRIE, MN, April 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce its participation in the upcoming 2023 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) conference. The event will be co-located with the Diabetic Limb Salvage (DLS) conference from April 26-30,... Read More

EDEN PRAIRIE, MN, April 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE , a leading medical technology company focused on the development and commercialization of non-invasive, regenerative medicine solutions, attended the 3rd Annual Leaders in Wound Healing Conference on April 18th and 19th in New Orleans, LA. The Leaders in Wound Healing Conference is an invitation-only event that brings together leaders in the... Read More

EDEN PRARIE, MN, April 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. “We are very pleased with the 2022 financial results and having achieved record annual revenues for the full year and... Read More

Eden Prairie, MN, March 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (OTCPK: SNWV), a leading provider of next-generation wound care products, will host a live conference call on Monday, April 3, 2023, at 9:00AM (EDT) to discuss a financial update and recent strategic initiatives. Telephone access to the call will be available by dialing the following numbers: Participant Listening : 1-877-407-0784... Read More

EDEN PRAIRIE, MN, Jan. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- SANUWAVE Health, Inc. (OTCQB: SNWV) (“SANUWAVE”), a leading provider of next-generation FDA-approved wound care products, is pleased to announce that its common stock commenced trading on the OTCQB today. About SANUWAVE SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological... Read More